Bharat Biotech concludes Final Analysis for COVAXIN®, claims 77.8 pc efficacy from phase-3 clinical trials
Hyderabad, Jul 3: Bharat Biotech, a global leader in vaccine development and innovation, announced Today safety and efficacy analysis data from Phase III clinical trials of COVAXIN®, a whole virion inactivated vaccine against SARS-CoV2, was…